LVCLF News Alert Living Cell Technologies Limited (LVCLF) 0.0600

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Living Cell Technologies Limited (LVCLF) 0.0600 $LVCLF

Hearing Disorders - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7w63tx/hearing_disorders) has announced the addition of the "Hearing Disorders - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hearing Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Adherex Technologies - Quark Pharmaceuticals - Novartis - Living Cell Technologies - Fate Therapeutics - Sound Pharmaceuticals - Pharmicell - Otologic Pharmaceutics - UniQure - AudioCure For more information visit http://www.researchandmarkets.com/research/7w..._disorders

'First-in-man' Implant of Regenerative Cell Therapy in Parkinson's Disease
PR Newswire - Thu Sep 19, 9:36PM CDT
Living Cell Technologies Limited (LCT) today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL(R) - a potential treatment for Parkinson's disease.

Hemophilia - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rvbm6c/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H2 2013" report to their offering. 'Hemophilia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Scope - A snapshot of the global therapeutic scenario for Hemophilia. - A review of the Hemophilia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemophilia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Baxter International Inc. Biogen Idec Inc. AstraZeneca PLC Nektar Therapeutics Cangene Corporation Lentigen Corporation Sangamo BioSciences, Inc. Pharming Group N.V. Novo Nordisk A/S BioMarin Pharmaceutical Inc. Chugai Pharmaceutical Co. Ltd Dong-A Pharmaceutical Co., Ltd. GTC Biotherapeutics, Inc. Octapharma AG Pain Therapeutics, Inc. Pfizer Inc. Bayer AG Living Cell Technologies Limited PROLOR Biotech, Inc. ReGenX Biosciences, LLC Alnylam Pharmaceuticals, Inc CSL Limited and many more... For more information visit http://www.researchandmarkets.com/research/rvbm6c/hemophilia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Huntington's Disease - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Huntington's Disease
M2 - Thu Sep 05, 9:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6nbttk/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Huntington's Disease - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. Huntington's Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Huntington's Disease. - A review of the Huntington's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Huntington's Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 - ACADIA Pharmaceuticals Inc. - Accera, Inc. - Auspex Pharmaceuticals - BrainStorm Cell Therapeutics Inc. - Ceregene, Inc. - CrystalGenomics, Inc. - GW Pharmaceuticals plc - Galenea Corp. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Ipsen S.A. - Isis Pharmaceuticals, Inc. - KineMed, Inc. - Living Cell Technologies Limited - Neuralstem, Inc. - Omeros Corporation - Oryzon - Pfizer Inc. - Prana Biotechnology Limited - Raptor Pharmaceuticals Corp. - SCYNEXIS, Inc. - Siena Biotech S.p.A. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - The Avicena Group, Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - Vybion, Inc. - Wellstat Therapeutics Corporation For more information visit http://www.researchandmarkets.com/research/6n...untingtons About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Huntington's Disease - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:33AM CDT
Research and Markets has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2013" report to their offering. 'Huntington's Disease - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Huntington's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Huntington's Disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Huntington's Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Huntington's Disease pipeline depth and focus of Indicatio




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hard Rock Tampa Bets $30 Million on Smoke-Free Play

Updated Category News Views 86

Cigarette smoke is getting treated like a revenue problem in Tampa, and that is a far more interesting signal than another ribbon-cutting photo. Seminole Hard Rock Hotel & Casino Tampa opened The Breeze: A Smoke-Free Experience by Hard Rock on Nov. 19, 2026, following a $30 million transformation aimed at guests who want clean-air casino time from arrival through...

Continue Reading
Global-E Faces Fresh Scrutiny After Muted Quarterly Outlook

Updated Category News Views 39

A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...

Continue Reading
CMS Audit Proposal Reopens Medicare Advantage Risk

Updated Category News Views 104

A regulator just tossed a rusted anchor into managed care's earnings model. CMS's proposed Comprehensive Regulations to Uncover Suspicious Healthcare rule, dubbed CRUSH and numbered CMS-6098-P, puts Medicare Advantage risk-adjustment audits back at center stage. The headline nobody can casually wave away: audit findings from sampled enrollees could be extrapolated across...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 107

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 31

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 118

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 73

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 149

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 64

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 55

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading

Top 5 Most Recently Viewed Articles

Cathie Wood's Bold Investment in BitMine's Ethereum Strategy

Updated Category News Views 200

ARK Invest's Strategic Move ARK Invest, under the dynamic leadership of Cathie Wood, has taken a significant step by investing in BitMine Immersion Technologies Inc. The firm acquired nearly 4.8 million shares of BitMine, valued at an impressive $182 million through multiple ARK funds. Focus on Ethereum Acquisition This investment reflects BitMine's ambitious plan to...

Continue Reading
23andMe Advances Chapter 11 Plans with Court Approvals

Updated Category News Views 421

23andMe Secures Court Approval in Chapter 11 Process In a significant development, 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), recognized for its innovative approach in genetics and biotechnology, has received critical approvals from a Bankruptcy Court related to its Chapter 11 petitions. These petitions were filed, propelling the Company into a...

Continue Reading
Insights into Archer Aviation's Stock and Market Movements

Updated Category News Views 190

Understanding Archer Aviation's Stock Dynamics In a notable shift, investors with significant capital are displaying a bullish outlook on Archer Aviation. This uptrend is primarily highlighted by the option trading activities surrounding the company. Recent Option Trading Insights The latest data reveals that there have been 20 trades observed within Archer Aviation's...

Continue Reading
PACT Capital Partners Sets New Standards in Investment Strategies

Updated Category News Views 471

PACT Capital Partners Launches as an Independent Investment Firm PACT Capital LLC, known as PACT Capital Partners, has officially launched as a pioneering independent investment firm focused on empowering middle-market alternative asset managers. With significant backing from major players, the firm aims to carve a niche in the competitive investment landscape. Strategic...

Continue Reading
Bakery Mixes Forecast 2026-2036: Growth and Trends

Updated Category News Views 61

Standardization Taking Center Stage in Bakery Mixes Imagine a bustling bakery floor, with the smell of fresh bread wafting through the air. Yet behind the scenes lies a streamlined operation driven by pre-formulated mixes, which is exactly where the global bakery mixes market finds its muscle these days. Valued at $6.5 billion in 2025, the market has its sights set on...

Continue Reading